#1 Clinical Trials Search in Europe

Nanobody Against Macrophage Mannose Receptor, Conjugated With 1,4,7-Triazacyclononane-N,N’,N”-Triacetic Acid, Labelled With Gallium Ga-68

Clinical trials are currently underway to investigate the use of a novel imaging agent called 68Ga-NOTA-Anti-MMR-VHH2 in patients with cardiac sarcoidosis and non-small cell lung cancer (NSCLC). This innovative drug is designed to detect specific types of immune cells called macrophages, which play a crucial role in these diseases. The trials aim to evaluate the effectiveness and safety of this imaging technique in diagnosing and monitoring these conditions, potentially offering new insights into disease progression and treatment response.

Table of Contents

What is 68Ga-NOTA-Anti-MMR-VHH2?

68Ga-NOTA-Anti-MMR-VHH2 is a new imaging agent being studied for its potential to detect inflammation in certain diseases. It’s also known by other names such as 68Ga-UZBRU-VHH2 or 68GaNOTA-anti-MMR-VHH2[1][2]. This compound is a nanobody (a small antibody fragment) that targets a specific protein called the macrophage mannose receptor (MMR) found on certain immune cells.

How does it work?

68Ga-NOTA-Anti-MMR-VHH2 works by binding to MMR-expressing macrophages, which are a type of immune cell often present in areas of inflammation. The compound is labeled with a radioactive element called gallium-68, which allows it to be detected using a special imaging technique called Positron Emission Tomography (PET). When injected into the body, it accumulates in areas where these specific macrophages are present, helping doctors visualize inflammation[1].

Conditions being studied

Currently, 68Ga-NOTA-Anti-MMR-VHH2 is being investigated for use in two main conditions:

  1. Cardiac Sarcoidosis: This is a rare inflammatory condition that affects the heart. It can cause various symptoms and potentially lead to heart problems if left untreated[1].
  2. Non-Small Cell Lung Cancer (NSCLC): This is a type of lung cancer. The imaging agent is being studied to see if it can help detect and visualize these tumors[2].

Current research

Two phase II clinical trials are currently underway to evaluate the effectiveness of 68Ga-NOTA-Anti-MMR-VHH2:

  1. A study focusing on cardiac sarcoidosis, aiming to detect heart inflammation using PET/CT imaging[1].
  2. A study evaluating its potential for imaging non-small cell lung cancer[2].

These studies aim to determine how well 68Ga-NOTA-Anti-MMR-VHH2 can detect inflammation or cancer compared to current standard imaging techniques.

Potential benefits

If successful, 68Ga-NOTA-Anti-MMR-VHH2 could offer several advantages:

  • Improved detection of inflammation in cardiac sarcoidosis, potentially leading to earlier diagnosis and treatment[1].
  • Better visualization of non-small cell lung cancer tumors, which could aid in diagnosis and treatment planning[2].
  • Possible use in monitoring response to treatment in both conditions[1].
  • No need for special patient preparation before imaging, unlike some current techniques[1].

Safety and side effects

As with any new medical compound, safety is a primary concern. The current studies are evaluating the safety of 68Ga-NOTA-Anti-MMR-VHH2, including monitoring for any adverse events or allergic reactions[1]. One study is also checking for the development of antibodies against the compound, which could potentially affect its effectiveness or safety[1].

Who can participate in these studies?

The studies have specific criteria for who can participate. Generally, participants must be:

  • At least 18 years old[1][2]
  • Diagnosed with cardiac sarcoidosis (for the cardiac study) or non-small cell lung cancer (for the lung cancer study)[1][2]
  • In relatively good overall health, without severe organ dysfunction or other life-threatening illnesses[1][2]

Pregnant or breastfeeding individuals are not eligible for these studies[1][2].

Conclusion

68Ga-NOTA-Anti-MMR-VHH2 is a promising new imaging agent that could potentially improve the detection and monitoring of inflammation in cardiac sarcoidosis and non-small cell lung cancer. While current research shows promise, it’s important to remember that this compound is still in the investigational stage. More studies are needed to fully understand its effectiveness and safety before it can be widely used in clinical practice.

Aspect Cardiac Sarcoidosis Trial NSCLC Trial
Main Objective Evaluate 68Ga-NOTA-Anti-MMR-VHH2 PET/CT imaging to detect cardiac sarcoid lesions Correlate 68Ga-NOTA-Anti-MMR-VHH2 uptake with immunohistological MMR-staining in NSCLC lesions
Patient Population Adults with histological or clinical ‘probable’ diagnosis of cardiac sarcoidosis Adults with NSCLC planned for resection or surgical biopsy
Key Inclusion Criteria Biopsy proven or probable cardiac sarcoidosis; Recent 18F-FDG and 13N-NH3 PET/CT scans Lesion ≥ 10 mm in size; Planned for resection or biopsy
Key Exclusion Criteria ECOG status 3 or 4; Pregnancy; Severe organ dysfunction ECOG status 3 or higher; Pregnancy; Active serious infection
Primary Endpoint Proportion of patients with cardiac sarcoidosis confirmed by 68Ga-NOTA-Anti-MMR-VHH2 imaging Immunohistological MMR score on excised tissue
Drug Dosage Maximum 370 MBq, intravenous injection Maximum 370 MBq, intravenous administration

FAQ

  • What is 68Ga-NOTA-Anti-MMR-VHH2? 68Ga-NOTA-Anti-MMR-VHH2 is a specialized imaging agent used in PET/CT scans. It's designed to bind to a specific receptor (MMR) on macrophages, a type of immune cell involved in various diseases. This allows doctors to visualize areas of inflammation or disease activity in the body.
  • What conditions are being studied using this imaging agent? The clinical trials are focusing on two main conditions: cardiac sarcoidosis (a type of heart inflammation) and non-small cell lung cancer (NSCLC). The imaging agent is being tested to see how well it can detect and monitor these diseases.
  • How is the imaging performed? The imaging is done using a PET/CT scanner. Patients receive an injection of 68Ga-NOTA-Anti-MMR-VHH2, and then images are taken to see where the agent accumulates in the body. This can help identify areas of disease activity or inflammation.
  • What are the potential benefits of this new imaging technique? If successful, this technique could provide a more accurate and specific way to diagnose and monitor cardiac sarcoidosis and NSCLC. It may help doctors better understand disease progression and response to treatment, potentially leading to improved patient care.
  • Are there any risks associated with the imaging procedure? As with any medical procedure, there are some risks. The clinical trials are designed to assess the safety of 68Ga-NOTA-Anti-MMR-VHH2, including monitoring for any adverse events or allergic reactions. The radiation exposure from the PET/CT scan is also considered in the risk assessment.

Ongoing Clinical Trials on Nanobody Against Macrophage Mannose Receptor, Conjugated With 1,4,7-Triazacyclononane-N,N’,N”-Triacetic Acid, Labelled With Gallium Ga-68

  • Study on Imaging Non-Small Cell Lung Cancer Using 68GaNOTA-Anti-MMR VHH2 in Patients

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Detecting Heart Inflammation in Cardiac Sarcoidosis Patients Using 68Ga-NOTA-Anti-MMR-VHH2 PET-CT Imaging

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • 68Ga-NOTA-Anti-MMR-VHH2: A specialized imaging agent used in PET/CT scans. It's a nanobody (a small antibody fragment) that targets the Macrophage Mannose Receptor (MMR) on certain immune cells, labeled with a radioactive element (Gallium-68) for detection.
  • Cardiac sarcoidosis: A condition where inflammation occurs in the heart tissue, often as part of a broader inflammatory disease called sarcoidosis. It can affect heart function and rhythm.
  • Non-small cell lung cancer (NSCLC): A type of lung cancer that is the most common form of the disease. It includes several subtypes of lung cancer that behave in similar ways, distinct from small cell lung cancer.
  • PET/CT: Positron Emission Tomography/Computed Tomography, an imaging technique that combines two types of scans to provide detailed pictures of both the structure and function of tissues in the body.
  • Macrophage: A type of white blood cell that is part of the immune system. Macrophages play important roles in inflammation and fighting infections.
  • MMR: Macrophage Mannose Receptor, a protein found on the surface of certain macrophages. It's the target of the imaging agent used in these studies.
  • Nanobody: A very small antibody fragment, derived from special antibodies found in camelids (like llamas and alpacas). They can be engineered to bind to specific targets in the body.

References

  1. http://clinicaltrials.eu/trial/detecting-heart-inflammation-in-cardiac-sarcoidosis-patients-using-68ga-nota-anti-mmr-vhh2-pet-ct-imaging/
  2. http://clinicaltrials.eu/trial/study-on-imaging-non-small-cell-lung-cancer-using-68ganota-anti-mmr-vhh2-in-patients/